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Abstract
Background—Cushing’ s syndrome (CS) is a severe condition with excess mortality and 
significant morbidity necessitating control of hypercortisolemia. There are few data documenting 
use of the steroidogenesis inhibitor metyrapone for this purpose.
Objective—The objective was to assess the effectiveness of metyrapone in controlling cortisol 
excess in a contemporary series of patients with CS.
Design—This was designed as a retrospective, multicenter study.
Setting—Thirteen University hospitals were studied.
Patients—We studied a total of 195 patients with proven CS: 115 Cushing’ s disease, 37 ectopic 
ACTH syndrome, 43 ACTH-independent disease (adrenocortical carcinoma 10, adrenal adenoma 
30, and ACTH-independent adrenal hyperplasia 3).
Measurements—Measurements included biochemical parameters of activity of CS: mean serum 
cortisol “day-curve” (CDC) (target 150 –300 nmol/L); 9 AM serum cortisol; 24-hour urinary free 
cortisol (UFC).
Results—A total of 164/195 received metyrapone monotherapy. Mean age was 49.6 ± 15.7 
years; mean duration of therapy 8 months (median 3 mo, range 3 d to 11.6 y). There were 
significant improvements on metyrapone, first evaluation to last review: CDC (91 patients, 722.9 
nmol/L [26.2 µg/dL] vs 348.6 nmol/L [12.6 µg/dL]; P < .0001); 9 AM cortisol (123 patients, 882.9 
nmol/L [32.0 µg/dL] vs 491.1 nmol/L [17.8 µg/dL]; P < .0001); and UFC (37 patients, 1483 
nmol/24 h [537 µg/24 h] vs 452.6 nmol/24 h [164 µg/24 h]; P = .003). Overall, control at last 
review: 55%, 43%, 46%, and 76% of patients who had CDCs, UFCs, 9 AM cortisol less than 331 
nmol/L (12.0 µg/dL), and 9 AM cortisol less than upper limit of normal/600 nmol/L (21.7 µg/dL). 
Median final dose: Cushing’ s disease 1375 mg; ectopic ACTH syndrome 1500 mg; benign adrenal 
disease 750 mg; and adrenocortical carcinoma 1250 mg. Adverse events occurred in 25% of 
patients, mostly mild gastrointestinal upset and dizziness, usually within 2 weeks of initiation or 
dose increase, all reversible.
Conclusions—Metyrapone is effective therapy for short- and long-term control of 
hypercortisolemia in CS.
Cushing’ s syndrome (CS) is a severe condition with excess mortality and significant 
morbidity necessitating effective biochemical control (1). Where a cause amenable to 
surgical intervention is identified, surgery at a center with appropriate expertise is the 
optimum management. Nevertheless, many patients need urgent control of severe or 
persisting hypercortisolemia. Options for medical treatment include steroidogenesis enzyme 
inhibitors suitable for all causes of CS (ketoconazole, metyrapone, mitotane), agents to 
suppress ACTH in Cushing’ s disease (CD), such as dopamine agonists and pasireotide, and 
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the glucocorticoid receptor antagonist, mifepristone (2, 3). The modern use of ketoconazole 
has recently been reported in a multicenter French Study (4), although its availability in the 
United States has been restricted after an Food and Drug Administration safety warning for 
hepatotoxicity in 2013 (5, 6), but it is widely available in Europe in 2015 (7).
The cortisol-lowering effect of metyrapone was described as early as 1958 by Liddle et al 
(8), with later reports confirming metyrapone as a potent inhibitor of the steroidogenesis 
enzyme 11ͤ-hydroxylase (8, 9). Since then, it has been used as a diagnostic test of adrenal 
reserve and to treat the hypercortisolism of CS. Despite its wide-spread use, data on 
metyrapone are scarce, with the largest study to date (including 91 patients) being published 
over 25 years ago (10). Here, we have assessed the effectiveness of metyrapone therapy in a 
contemporary series of patients with CS, by performing a retrospective study of patients 
treated in the United Kingdom.
Materials and Methods
A multicenter, retrospective study was performed across 13 University hospital centers in 
England and Wales, members of the United Kingdom Endocrine Neoplasia Collaboration. 
Patients treated with metyrapone were identified through pharmacy records and electronic 
databases. Patients with a diagnosis of CS and treated with metyrapone between 1997 and 
2013 were included.
The same proforma was used in all centers to record anonymized data. Data were gathered 
from case records and electronic record systems. Baseline, demographic and safety data, the 
indication for treatment and dose of metyrapone therapy, any therapeutic intervention and 
any recorded adverse events were documented. Monitoring tests included early morning (9 
AM) serum cortisol, 24-hour urinary free cortisol (UFC), serum potassium, plasma ACTH, 
and serum cortisol “day-curves” (CDCs). In CDCs multiple samples for serum cortisol are 
collected across the day with the mean calculated (11). The majority (91%) of CDCs 
consisted of 4 or 5 serum cortisol samples (minimum 3, maximum 8, median 4). All tests 
performed during the monitoring period were collected and analyzed. All centers used 
immunoassay-based cortisol assays.
Patients were treated either with a dose titration regimen, ie, metyrapone dose was up-
titrated according to response to achieve a biochemical target for cortisol, or a block-and-
replace regimen, where the dose of metyrapone was quickly up-titrated to achieve blockade 
of cortisol synthesis and a replacement dose of glucocorticoid was added to provide 
background physiological levels.
Biochemical targets for treatment (eucortisolemia) were defined as a mean CDC value of 
150–300 nmol/L (10.9 µg/dL), which has been shown to equate to a normal cortisol 
production rate as assessed by stable isotopic methodology (11), a UFC level below the 
upper limit of normal (ULN) for the assay used or a 9 AM serum cortisol within target. 
Although 9 AM serum cortisol is occasionally being used as a sole test for evaluating 
patients’  response to treatment, there is currently no standardized agreement for what values 
of this test represent appropriate control. Two different levels of target 9 AM cortisol were 
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therefore assessed: 1) below the ULN for the assay used, or less than 600 nmol/L (21.7 
µg/dL) if the ULN was higher than this value; and 2) a recommended value of 331 nmol 
(12.0 µg/dL) (12). Cortisol levels were reported in nmol/L and divided by 27.59 to calculate 
the equivalent value in µg/dL. There was a wide range of UFC assays used with variable 
reference range of normal values; therefore, UFC values were converted to multiples of the 
ULN for the assay and this value was used for statistical comparisons. Patients with 
sufficient monitoring data (ie, at least one test as described above repeated at least twice 
during the study period) were included in the efficacy analysis. For the efficacy analyses we 
compared the mean values at each monitoring test (CDC, 9 AM serum cortisol, UFC) before 
treatment with 1) the mean values on the last review on treatment (diagnosis vs last review); 
and 2) the mean of all tests performed in all patients during treatment (diagnosis vs 
treatment), unless otherwise stated. The change of the biochemical markers between 1) 
baseline (at diagnosis/pretreatment) and the last review on treatment for 9 AM cortisol; and 2) 
the first and the last biochemical review for CDCs (CDCs were not routinely performed 
before initiation of treatment) on treatment was also analyzed.
Statistical analysis was performed using the 2-tailed Student’ s t test (GraphPad prism 6.0; 
GraphPad Software, Inc). Except where stated, values given are means ± SDs. P < .05 was 
considered significant. The study was approved as an institutional case notes review at each 
participating center.
Results
Baseline characteristics
A total of 195 patients were treated with metyrapone across the 13 centers. Most patients 
had CD (115 patients, 37 macroadenoma) with the remainder having ectopic ACTH 
syndrome (EAS) (37), adrenocortical carcinoma (ACC) (10), and benign adrenal disease (30 
adrenal adenoma [AA], ACTH-independent macronodular adrenal hyperplasia [2] and 
primary pigmented nodular adrenal hyperplasia [1]) (Table 1). There was a female 
predominance in all causes of CS except EAS (female patients:74% CD, 49% EAS, 86% 
AA, and 80% ACC). Patients were treated with metyrapone between 1997 and 2013 (83% 
between 2007 and 2013). The average duration of treatment was 8 months (median 3 mo, 
range 3 d to 11.6 y). At initiation of treatment, there was a wide age distribution, with 76% 
of patients aged 30–69 years (age range 1–81, median age 48, average age 49.6 ± 15.7 y), 
and 32% of patients (n = 63) were women in the reproductive ages 18–45 (Figure 1). 
Comorbidities at presentation included hypertension (64.6%) and diabetes mellitus (35.3%). 
For patients with CD, baseline contrast-enhanced pituitary magnetic resonance imaging was 
positive in all patients with a macroadenoma and in 53 out of 72 (73%) patients with a 
microadenoma.
The main indication for metyrapone therapy was the control of severe symptoms of CS (CD 
58%, EAS 77%, benign adrenal disease 44% and ACC 80%). Medical therapy was initiated 
as part of routine local practice in 8 out of 13 centers for the management of patients after 
diagnosis and before definitive therapy (eg, surgery) regardless of the level of 
hypercortisolemia in a smaller number of patients (CD 25%, EAS 11%, benign adrenal 
disease 37%, ACC 0%). Delay in definitive treatment for CS (either due to medical reasons 
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or requested by the patient) was a reason for starting medical therapy in 19% of patients. A 
total of 25/195 patients (12.8%) received only cortisol-lowering treatment for their CS 
because of either inconclusive surgical target, palliation of aggressive malignancy (ACC or 
lung carcinoma), patients’  own preference, or high surgical risk.
Biochemical changes during metyrapone treatment
Monitoring data during metyrapone therapy were available for 193 patients. The frequency 
of the monitoring visits was variable with some centers opting for inpatient tests at the 
introduction of treatment and other centers using outpatient monitoring every few weeks; 
81% of patients were treated with dose titration and 19% with “block-and-replace.”
Metyrapone monotherapy
A total of 164 patients received metyrapone monotherapy, and all monitoring tests showed 
significant improvement during treatment (Table 2). At the last review, 55%, 43%, 46%, and 
76% of patients who had CDCs, UFCs, 9 AM cortisol less than 331 nmol/L (12.0 µg/dL), and 
9 AM cortisol less than ULN/600 nmol/L (21.7 µg/dL) were controlled.
Ninety-one patients were monitored with CDCs during treatment; 47/91 (52%) patients 
achieved a mean CDC less than 300 nmol/L (10.9 µg/dL) during treatment (ie, normalized 
cortisol target) and 81% of those who did not normalize had an improvement between the 
first and the last assessment on treatment (Figure 2A). Patients on a block-and replace 
regimen were more likely to achieve have a mean CDC less than 150 nmol/L. A total of 123 
patients had 9 AM serum cortisol levels monitored; during treatment 83% (102/123) had a 9 
AM serum cortisol bellow 600 nmol/L (21.7 µg/dL) or the ULN for the assay used and 56% 
(69/123) had a 9 AM level below 331 nmol/L (12.0 µg/dL) with 86% of patients showing an 
improvement in cortisol levels (mean improvement 566 nmol/L, median 467 nmol/L) even if 
these biochemical targets were not achieved (Figure 2B).
Effectiveness of metyrapone monotherapy before surgery
The majority (124/164) of patients treated with metyrapone monotherapy received treatment 
before any surgical intervention (CD 81, EAS 11, benign adrenal disease 25, ACC 7) for an 
average of 4.0 months. There was a significant improvement in the biochemical targets 
during metyrapone therapy (Table 2). At the last review, 50%, 35%, 40%, or 72% of patients 
who had CDCs, UFCs, 9 AM cortisol less than 331 nmol/L (12 µg/dL), or 9 AM cortisol less 
than ULN/600 nmol/L (21.7 µg/dL) were controlled (for dose see Table 3).
At the time of the first normalization, 91% were treated with dose titration and 9% with 
block-and-replace. In ACTH-dependent disease, plasma ACTH levels were measured too 
sporadically to allow meaningful analysis. A total of 10/18 (56%) patients who did not 
achieve a biochemical target also had a reduction of cortisol levels.
Metyrapone monotherapy as secondary treatment
Thirty-one patients (29 CD, 1 EAS, 1 benign adrenal disease) received metyrapone as 
secondary treatment after either surgery (21) or pituitary radiotherapy (17): 21/31 as 
monotherapy and 10/31 as combination therapy. Of the patients who received metyrapone 
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after primary surgery, 19 had pituitary surgery for CD (9 had a macroadenoma), 1 had a 
pancreatectomy for a neuroendocrine tumor, and 1 a repeat adrenalectomy for an incomplete 
excision of an AA. Of the patients with CD, 7/19 also received pituitary radiotherapy. For 
the patients on monotherapy (n = 21), the mean starting dose of metyrapone was 1300 mg 
(Table 3). Patients were treated for an average of 17.1 months. At the last review, 76%, 78%, 
or 94% of patients who had CDCs, 9 AM cortisol less than 331 nmol/L (12 µg/dL) or 9 AM 
cortisol less than ULN/600 nmol/L (21.7 µg/dL) were controlled. At normalization, 35% 
(6/17) of patients were treated with block-and-replace and 65% (11/17) with dose titration. 
Biochemical tests (mean CDC and 9 AM cortisol) improved during treatment (Table 2). Only 
4 patients had UFCs during treatment, therefore the change in UFC for this group of patients 
was not analyzed.
Long-term treatment with metyrapone monotherapy
Monitoring data were available on 38 patients who received metyrapone monotherapy for 
longer than 6 months. The average duration of treatment was 18.6 months, and 6 patients 
had block-and-replace at some point during their treatment. Biochemical tests improved 
during treatment (Table 2). Overall, eucortisolemia was achieved in 72% (18/25) of patients 
who had CDCs, 77% (24/31) and 94% (29/31) of patients who had 9 AM cortisols (based on 
<331 nmol/L or <ULN/600 nmol/L cut-offs) or 64% (9/14) of patients who had UFCs.
Starting and final dose (Table 3)
Mean, median, and range of doses on metyrapone monotherapy at the initiation of treatment 
and at final review are shown in Table 3. On block-and-replace the starting dose of 
metyrapone was higher (mean dose 1432 mg vs 939.2 mg, P < .0001). There were, however, 
no significant differences in the mean 9 AM serum cortisol levels during treatment or at the 
last review in the 2 groups (block-and-replace group during treatment 461.2 nmol/L [16.7 
µg/dL] vs dose titration group 507.8 nmol/L [18.4 µg/dL]; P = .50, last review 510.8 nmol/L 
[18.5 µg/dL] vs 376.3 nmol/L [13.6 µg/dL]; P = .26).
Combination treatment
Twenty-nine patients were treated with a combination of metyrapone and other cortisol-
lowering medication (mainly ketoconazole or mitotane, 7 patients had combination 
treatment from the start of therapy, whereas in 22, combination therapy was instigated after 
initial treatment with metyrapone). The CDC or 9 AM serum cortisol levels at diagnosis were 
not significantly different in the patients treated with combination compared with the 
patients treated with metyrapone monotherapy (CDC combination 830.8 nmol/L [30.1 
µg/dL] vs monotherapy 722.9 nmol/L [26.2 µg/dL]; P = .558, and 9 AM cortisol, combination 
1149 nmol/L [41.6 µg/dL], vs monotherapy 882.9 nmol/L [32.0 µg/dL]; P = .077). There 
was a significant improvement in CDC and 9 AM serum cortisol during treatment (Table 2). 
Only 3 patients on combination therapy had UFC monitoring, pre-cluding analysis. At the 
last review, 47%, 52%, or 75% of patients who had CDCs, 9 AM cortisol less than 331 
nmol/L (12 µg/dL), or 9 AM cortisol less than ULN/600 nmol/L (21.7 µg/dL) were 
controlled. Patients who at the last review were controlled on a dose titration regimen based 
on CDCs and UFCs received 1850-mg mean total daily dose (median 1500 mg, range 750–
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6000 mg). No subgroup analysis for efficacy was performed for this group due to small 
numbers.
Safety considerations
Side effects were noted in 48/195 patients (25%): 88% were managed as outpatients, 
whereas 12% (7/57 events) required either admission for evaluation or prolongation of a 
current admission. The rate of adverse events in patients on therapy for more than 6 months 
was 11% (4/38 patients). There were no pregnant women and no deaths recorded due to an 
adverse event. The average dose of metyrapone at the time of an adverse event was 1600 mg. 
Gastrointestinal (GI) upset (23%) and hypoadrenalism (7%, symptoms of dizziness, 
hypotension, with biochemical confirmation) were the most common side effects. Most 
adverse events (39/56) occurred within 15 days of initiation of metyrapone or after a dose 
increase. GI upset and dizziness were the main reasons for discontinuing treatment. Patients 
with confirmed hypoadrenalism were managed either by addition of glucocorticoid (regimen 
change to a block-and-replace) or temporary cover with glucocorticoid and simultaneous 
reduction of metyrapone dose. In 15% of cases, the metyrapone dose was reduced. In 12 
cases (23%), metyrapone was withdrawn temporarily or permanently, with 11/12 showing 
full resolution, and in 1, symptoms continued but became less severe, muscle aches at 
presentation worsened during metyrapone therapy but returned to pretreatment levels after 
drug withdrawal. Symptoms of hyperandrogenism were not frequent; hirsutism was not 
reported, and there was only 1 case of worsening acne during treatment. Similarly, edema 
was only reported in 1 case, but the causative drug was thought to be a calcium channel 
blocker. Hypoglycemia was reported in 3 patients on diabetic medications and was 
associated with improvement of hypercortisolism.
Potassium levels were monitored and actively treated at presentation and during therapy. In 
138 patients on metyrapone monotherapy, with no other treatment interventions for their CS, 
mean potassium levels increased from 3.68 to 3.90 nmol/L (P = .003) during treatment 
(Figure 3).
Discussion
We report the effectiveness of metyrapone in clinical practice for the treatment of CS. To our 
knowledge, this is the largest study of metyrapone use as either monotherapy or metyrapone 
in combination with other cortisol-lowering medications. Overall, more than 80% of patients 
showed an improvement in levels of circulating cortisol with over 50% achieving 
biochemical eucortisolemia when on monotherapy when assessed by the stringent criterion 
of control on a CDC. It is likely that additional therapies were added because of the severity 
of disease and clinician preference, but the retrospective and multicenter nature of our study 
precludes a formal assessment of this. Furthermore, our data support that metyrapone mono-
therapy is an effective treatment for hypercortisolemia either before or after surgical 
intervention to the primary cause of CS.
Metyrapone is widely used in CS in the United Kingdom and other countries but less so in 
the United States. To date, the efficacy of metyrapone in reducing cortisol levels in CS has 
been described in case reports and small case series (13–16), with the largest series reported 
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25 years ago by Verhelst et al (10). In this single center experience, metyrapone was 
effective in reducing cortisol levels in 75% of 91 patients with CD, EAS, and ACC based on 
a mean CDC level less than 400 nmol/L that is higher than the more stringent less than 300 
nmol/L level that we used in this study. Most patients in the Verhelst study received a short 
course of metyrapone except for 24 patients who had metyrapone for a median of 27 months 
after radiotherapy to the pituitary gland. Smaller studies have reported the efficacy of 
metyrapone in patients with CD undergoing radiotherapy (13–15) and EAS (17). Overall, in 
200 cases of metyrapone monotherapy published in the English literature, biochemical 
control was achieved in 75% (18). We report similar efficacy. It is of note, however, that 
most patients with CD in our study here were not treated in conjunction with pituitary 
radiotherapy, and there did not appear to be evidence of an escape of control phenomenon, 
although we cannot comment on plasma ACTH levels during monitoring.
Ketoconazole, an antifungal agent and inhibitor of adrenal steroidogenesis, has also been 
widely used as a cortisol-lowering agent in CS. In the largest report to date, Castinetti et al 
reported biochemical control in 50% of patients with CS treated with ketoconazole 
monotherapy with biochemical improvement in 75% and evidence of regression of clinical 
features in up to 60% (4). Overall, in 456 published cases treated with ketoconazole 
monotherapy, 60% achieved control (18). Combination treatment with metyrapone and 
ketoconazole is commonly used (19), especially for the rapid control of hypercortisolism 
before definite treatment. In 22 patients with severe hypercortisolism due to EAS (n = 14) 
and ACC (n = 8), combination treatment of metyrapone and ketoconazole dramatically 
improved UFC levels within a month of treatment, whereas half of the patients also started 
mitotane during this time (20). Kamenický et al (21) used a triple-medication protocol with 
simultaneous administration of ketoconazole, metyrapone and mitotane in 11 patients with 
hypercortisolism and life-threatening complications as an alternative to bilateral 
adrenalectomy; all patients showed rapid clinical and biochemical improvement. In both 
studies, the initial biochemical control is mainly due to the combination of ketoconazole and 
metyrapone as the onset of action of mitotane is usually delayed by several weeks due to 
accumulation in adipose tissue (22). In 1 of the few prospective studies of medical treatment 
of CD, Feelders et al (23) used a stepwise approach to treat 17 patients with CD with a 
combination of pituitary and adrenal-acting agents. Patients were initially treated with the 
somatostatin analog pasireotide, followed by cabergoline, and ketoconazole was later 
introduced if biochemical control was suboptimal. Nine out of 17 patients normalized with 
pasireotide/cabergoline and ketoconazole induced biochemical control in 6/8 remaining 
patients (75%) within 20 days of treatment (23).
Metyrapone increases cortisol metabolites in the serum and urine due to the predominant 
inhibition of 11ͤ-hydroxylase, and to a lesser extent the other steroidogenesis enzymes (10, 
24). In particular, 11-deoxycortisol levels may become profoundly elevated in patients on 
metyrapone therapy, especially in patients with CD (25, 26). 11-deoxycortisol is structurally 
very similar to cortisol and may cross-react with cortisol immunoassays resulting in an 
overestimation of serum cortisol values in patients on metyrapone (26). The importance of 
this is underscored by the fact that symptoms of adrenal insufficiency may overlap those of 
side effects of metyrapone. Thus, cortisol estimation by more accurate methods such as mass 
spectrometry is advisable, and should be used where available (27). Moreover, it is likely 
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that our data may underestimate the efficacy of metyrapone therapy when assessing serum 
measurements of cortisol as the cross-reactivity in immunoassays results in approximately 
20% elevated bias (25).
Hypokalemia has been described as a potential serious complication of metyrapone therapy 
(24, 28) due to the increase in steroid precursors with mineralocorticoid activity (11-
deoxycorticosterone). Our data suggest that clinicians using metyrapone are well aware of 
the importance of monitoring and managing serum potassium levels, because we found that 
these increase significantly with supportive measures during treatment. It is important to 
stress, however, that such active monitoring is required, because hypokalemia is also a 
potentially harmful feature of CS. The most common adverse effects observed were mild GI 
symptoms and hypoadrenalism, the latter a positive response to treatment provided that it is 
recognized and managed early. Patients on long-term treatment are more likely those who 
tolerate metyrapone well, therefore the rate of adverse events was favorable in this subgroup. 
Interestingly, hirsutism was not reported.
This study carries the limitations imposed by its retrospective design. Furthermore, there is 
currently no standardized monitoring and dosing regimen for patients on metyrapone 
therapy. The monitoring of hypercortisolemia in patients with CS on medical treatment is 
important to ensure that patients are treated with the correct dose and that hypoadrenalism, if 
present, is recognized early; measurement of serum cortisol allows this. Even though the 
study was conducted in University centers with significant expertise in the management of 
CS, the choice of biochemical monitoring test and frequency of monitoring varied. This has 
affected the uniformity of the data presented. During the period of the study, the common 
clinical practice was to aim for a 9 AM cortisol bellow the ULN for the assay used or less 
than 600 nmol/L. Any results above these levels would prompt up-titration of the dose or 
addition of a second agent. Therefore, we have reported these cut-offs as the criteria for 
normalization of hypercortisolemia. More stringent 9 AM serum cortisol levels to define 
control have been proposed recently (12), with suggested values below 331 nmol/L (12 µg/
dL). It is not possible to know whether clinicians would have up-titrated the dose of 
metyrapone had this criterion been used, and therefore, we can only speculate that the 
overall control when using this criterion might have been better if applied in practice.
In conclusion, our data show that metyrapone is effective and safe in treating 
hypercortisolemia in patients with CS.
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CS Cushing’ s syndrome
EAS ectopic ACTH syndrome
UFC urinary free cortisol
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Figure 1. 
Age of patients at initiation of metyrapone therapy and diagnosis of CS.
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Figure 2. 
Mean serum CDC and 9 AM serum cortisol levels during treatment with metyrapone 
monotherapy. A, Change in mean CDC in 91 patients treated with metyrapone monotherapy 
between the first review after initiation of metyrapone and the last review on treatment: 52% 
(47/91) patients achieved biochemical normalization, 89% showed an improvement. B, 
Change in the pretreatment 9 AM cortisol level in 123 patients treated with metyrapone 
monotherapy and the last review on treatment: 86% showed an improvement; 102 (83%) 
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patients had a 9 AM serum cortisol value below the ULN for the assay used or 600 nmol/L 
(whichever was lowest) and 69 (56%) had a 9 AM level less than 331 nmol/L.
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Figure 3. 
Potassium levels before and during metyrapone monotherapy in 138 patients.
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Table 1
Baseline Patient Characteristics
Etiology Number of Patients Female/Male Average Age at Diagnosis (y) Average Age at Metyrapone Onset (y)
CD 115a 85/30 45.9 47.4
   Macroadenoma 37
   Microadenoma 77
EAS 37 18/19 52.6 52.9
Benign adrenal disease 33 27/6 50.3 51.2
   AA 30 26/4
   AIMH 2 1/1
   PPNAD 1 0/1
ACC 10 8/2 56.0 56.4
Abbreviations: AIMH, ACTH-independent macronodular hyperplasia; PPNAD, primary pigmented nodular adrenal disease.
aSize of adenoma not available in 1 patient.
J Clin Endocrinol Metab. Author manuscript; available in PMC 2017 April 17.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Daniel et al. Page 18
Table 2
Change in Biochemical Markers During Metyrapone Therapy (Mean Values)
Number of Patients Pretreatment During Treatmenta
At the Last Review on 
Treatmenta
Monotherapy
    Overall 164
    Mean CDCb 91 722.9 nmol/L (26.2 
µg/dL)
396.4 nmol/L (14.4 µg/dL), P < .
0001
348.6 nmol/L (12.6 µg/dL), 
P < .0001
    9 AM serum cortisol 123 882.9 nmol/L (32.0 
µg/dL)
527.8 nmol/L (19.1 µg/dL), P < .
0001
491.1 nmol/L (17.8 µg/dL), 
P < .0001
    UFC 37 1483 nmol/24 h (537 
µg/24 h)
1070 nmol/24 h (388 µg/24 h), P 
= .588
453 nmol/24 h (164 µg/24 
h), P = .003
    UFC:ULNc 37 7.2 5.4, P = .556 2.5, P = .020
Before surgery 124
    Mean CDC 70 691.5 nmol/L (25.1 
µg/dL)
407.7 nmol/L (14.8 µg/dL), P < .
0001
351.5 nmol/L (12.7 µg/dL), 
P < .0001
    9 AM serum cortisol 82 779.7 nmol/L (28.3 
µg/dL)
508.0 nmol/L (18.4 µg/dL), P < .
0001
495.6 nmol/L (18.0 µg/dL), 
P < .0001
    UFC 25 1318 nmol/24 h (478 
µg/24 h)
1049 nmol/24 h (380 µg/24 h), P 
= .704
525 nmol/24h (190 µg/24 
h), P = .008
    UFC:ULN 25 6.4 5.5, P = .553 2.9, P = .014
Secondary therapy 21
    Mean CDC 12 478.5 nmol/L (17.3 
µg/dL)
311.0 nmol/L (11.3 µg/dL), P = .
001
248.9 nmol/L (9.0 µg/dL), 
P = .001
    9 AM serum cortisol 17 659.6 nmol/L (23.9 
µg/dL)
361.3 nmol/L (13.1 µg/dL), P = .
0001
281.3 nmol/L (10.2 µg/dL), 
P = .002
    Long-term treatmentd 38
    Mean CDC 24 451.4 nmol/L (16.4 
µg/dL)
339.5 nmol/L (12.3 µg/dL), P = .07 366.2 nmol/L (13.3 µg/dL), 
P = .35
    9 AM serum cortisol 31 734.2 nmol/L (26.6 
µg/dL)
428.2 nmol/L (15.5 µg/dL), P < .
0001
384.5 nmol/L (13.9 µg/dL), 
P < .0001
Combination therapy 29
    Mean CDC 17 830.8 nmol/L (30.1 
µg/dL)
314.2 nmol/L (11.4 µg/dL), P < .
0001
278.7 nmol/L (10.1 µg/dL), 
P < .0001
    9 AM serum cortisol 20 1149 nmol/L (41.6 
µg/dL)
522.9 nmol/L (19.0 µg/dL), P < .
0001
471.9 nmol/L (17.1 µg/dL), 
P = .003
aStatistical analysis is compared with the pretreatment value.
b
Mean cortisol of a CDC.
cUFC to the ULN for the assay used.
d
More than 6 months.
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Table 3
Total Daily Dosage of Metyrapone for Patients Treated With a Dose Titration Regimen
Starting Dose (mg)a Final Dose (mg)a
Metyrapone monotherapy (n = 164) 1040, 750, 250–3750 1425, 1500, 500–4000
    CD (n = 96) 1020, 750, 250–3000 1380, 1375, 500–3500
    EAS (n = 27) 1260, 1000, 500–3750 1990, 1500, 500–3750
    Benign adrenal disease (n = 31) 820, 1000, 250–2250 1210, 750, 500–4000
    ACC (n = 10) 1230, 1500, 750–2000 1190, 1250, 750–1500
Presurgery (n = 124) 1000, 750, 500–2250 1440, 1500, 500–4000
    CD (n = 81) 980, 750, 500–2250 1400, 1500, 500–3500
    EAS (n = 11) 1200, 1500, 500–2000 2120, 2250, 500–3750
    Benign adrenal disease (n = 25) 880, 750, 500–2250 1230, 1000, 500–4000
    ACC (n = 7) 1250, 1500, 750–2000 1080, 1000, 750–1500
Secondary treatment (n = 25) 1300, 1125, 500–3000 1400, 1500, 500–2250
Long-term treatment (>6 mo) (n = 38) 940, 750, 500–3000 1560, 1500, 500–4000
aGiven in 2–4 divided doses; mean, median, range.
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